Subscribe to RSS
Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update
Patients with novel coronavirus disease 2019 (COVID-19) are at significantly increased risk for mortality and morbidity. Current management remains supportive care, ranging from symptomatic outpatient management to full–intensive care support, including intravenous fluids, invasive, and non-invasive oxygen supplementation. In patients with septic shock, treatment with antibiotics and vasopressors are recommended to keep mean arterial pressure (MAP) ≥ 65 mm Hg and lactate < 2 mmol/L. Because of the lack of effectiveness and possible adverse effects, routine corticosteroids should be avoided unless they are indicated for another reason (exacerbation of asthma or chronic obstructive pulmonary disease [COPD], and septic shock in whom fluids and vasopressors do not restore hemodynamic stability). There is currently no sufficient evidence of efficacy of hydroxychloroquine/chloroquine, remdesivir, and other antivirals in the treatment or prevention of COVID-19. Limited evidence shows that COVID-19 convalescent plasma can be used as a treatment of COVID-19 without the occurrence of severe adverse events. Drug regulatory agencies granted an emergency-use authorization of chloroquine/hydroxychloroquine and remdesivir to treat patients when a clinical trial is not available or participation is not feasible. Chloroquine and hydroxychloroquine are associated with QT interval prolongation and life-threatening cardiac arrhythmia in patients with pre-existing cardiovascular disease. Guidelines are issued for use of convalescent plasma in patients with serious or immediately life-threatening COVID-19. Data from several ongoing randomized controlled trials will provide further evidence regarding the safety and efficacy of these drugs for the treatment of COVID-19.
Keywordsnovel coronavirus disease 2019 - severe acute respiratory syndrome-coronavirus-2 - World Health Organization - hydroxychloroquine - chloroquine - remdesivir - convalescent plasma - vaccines
Article published online:
16 May 2020
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 World Health Organization. Country & Technical Guidance - Coronavirus disease (COVID-19). Available at:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance Accessed April 19, 2020
- 2 Gautret P, Lagier JC, Parola P. et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis 2020; (e-pub ahead of print) DOI: 10.1016/j.tmaid.2020.101663.
- 3 Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with corona virus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; (e-pub ahead of print) DOI: 10.1001/jamainternmed.2020.0994.
- 4 Grein J, Ohmagari N, Shin D. et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2007016.
- 5 European Medicines AgencySummary on compassionate use. Available at: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf. Accessed April 19, 2020)
- 6 Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; (e-pub ahead of print) DOI: 10.1093/jac/dkaa114.10.
- 7 Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents 2020; (e-pub ahead of print) DOI: 10.1016/j.ijantimicag.2020.105938.
- 8 Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14 (01) 72-73
- 9 Gautret P, Lagier JC, Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; (e-pub ahead of print) DOI: 10.1016/j.ijantimicag.2020.105949.
- 10 Chen Z, Hu J, Zhang Z. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Med Rxiv 2020; doi DOI: 10.1101/2020.03.22.20040758.
- 11 Chen J, Liu D, Liu L. et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020; 49 (01) doi DOI: 10.3785/j.issn.1008-9292.2020.03.03.
- 12 Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.4742.
- 13 Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med 2020; (e-pub ahead of print) DOI: 10.1016/S2213-2600(20)30172-7.
- 14 Molina JM, Delaugerre C, Le Goff J. et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; (e-pub ahead of print) DOI: 10.1016/j.medmal.2020.03.006.
- 15 U.S. Food and Drug AdministrationRequest for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. https://www.fda.gov/media/136534/download Accessed April 19, 2020
- 16 Cao B, Wang Y, Wen D. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2001282.
- 17 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al. Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (01) 80-90
- 18 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 2006; 145 (08) 599-609
- 19 Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20 (04) 398-400
- 20 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.4783.
- 21 Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15 (05) 327-347
- 22 Thanh Le T, Andreadakis Z, Kumar A. et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; (e-pub ahead of print) DOI: 10.1038/d41573-020-00073-5.